CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 86 filers reported holding CUREVAC N V in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $495,243 | -31.1% | 72,510 | +5.1% | 0.00% | – |
| Q2 2023 | $719,178 | +93.4% | 69,019 | +29.4% | 0.00% | – |
| Q1 2023 | $371,878 | +23.1% | 53,354 | +6.5% | 0.00% | – |
| Q4 2022 | $302,030 | -8.8% | 50,088 | +19.3% | 0.00% | – |
| Q3 2022 | $331,000 | -74.9% | 41,990 | -56.7% | 0.00% | -100.0% |
| Q2 2022 | $1,320,000 | -15.7% | 96,989 | +21.6% | 0.00% | 0.0% |
| Q1 2022 | $1,565,000 | -34.7% | 79,781 | +14.2% | 0.00% | 0.0% |
| Q4 2021 | $2,396,000 | -41.4% | 69,851 | -6.7% | 0.00% | -50.0% |
| Q3 2021 | $4,089,000 | -33.5% | 74,865 | -10.6% | 0.00% | -33.3% |
| Q2 2021 | $6,153,000 | -85.9% | 83,729 | -82.5% | 0.00% | -87.5% |
| Q1 2021 | $43,749,000 | +319.2% | 478,342 | +271.6% | 0.02% | +300.0% |
| Q4 2020 | $10,436,000 | +135.2% | 128,739 | +35.0% | 0.01% | +100.0% |
| Q3 2020 | $4,438,000 | – | 95,330 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 3,134,780 | $286,707,000 | 46.92% |
| Ally Bridge Group (NY) LLC | 110,000 | $10,061,000 | 1.93% |
| Parametrica Management Ltd | 44,695 | $3,968,000 | 1.91% |
| Renaissance Capital LLC | 123,983 | $11,339,000 | 1.68% |
| Samsara BioCapital, LLC | 95,318 | $8,718,000 | 1.61% |
| Ikarian Capital, LLC | 360,000 | $32,925,000 | 1.11% |
| SECTOR GAMMA AS | 25,000 | $2,287,000 | 0.42% |
| Fosun International Ltd | 50,000 | $4,438,000 | 0.35% |
| Ikarian Capital, LLC | 100,000 | $9,145,000 | 0.31% |
| Baillie Gifford | 5,830,101 | $533,221,000 | 0.30% |